Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 1/2 1

Status

Recruiting 2Active not recruiting 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 68Sarcoma 12CNS 12Thoracic 8Tumor-Agnostic 5Genitourinary 5Gynecologic 4Other solid neoplasm 3Endocrine 2Breast 2Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Neoplasm Metastasis 3Endometrial Neoplasms 3Colorectal Neoplasms 3Ovarian Neoplasms 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Lung Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Acinar Cell 1

Interventions

Paclitaxel 74pembrolizumab 59Carboplatin 55Bevacizumab 54Specimen Handling 47Magnetic Resonance Spectroscopy 38Cisplatin 32olaparib 28Gemcitabine 25liposomal doxorubicin 24Biopsy 20Taxes 18Topotecan 17Nivolumab 17Doxorubicin 15Cyclophosphamide 15Immunoglobulin G 14Disulfides 14niraparib 12fludarabine 12lenvatinib 11Surveys and Questionnaires 11Letrozole 11atezolizumab 10Drug Therapy 10durvalumab 9Fulvestrant 9Docetaxel 9Brachytherapy 9mirvetuximab soravtansine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Irinotecan × Gynecologic × 90 days × Clear all
NCT06459180 2026-05-27

TroFuse-020

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
686 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT06974110 2026-04-15

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

MOMA Therapeutics

Phase 1 Recruiting
132 enrolled
GastrointestinalGynecologic

Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04657068 2026-03-18

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Artios Pharma Ltd

Phase 1/2 Recruiting
442 enrolled
GastrointestinalGynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Carcinoma, Acinar Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡